ISRCTN98387311 https://doi.org/10.1186/ISRCTN98387311

Radiotherapy for pathological stage Ia and IIa (Upper) Hodgkin's disease

Submission date	Recruitment status	[_] Prospectively registered
01/07/2001	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
01/07/2001	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
01/02/2012	Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
HD1-82

Study information

Scientific Title

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Non randomised trial

Primary study design
Interventional

Study type(s)

Health condition(s) or problem(s) studied
Lymphoma (Hodgkin's)

Interventions
This is a non randomised study, patients are grouped according to site and stage of disease:

1. Group A: Patients with pathological stage Ia (neck), IIa (neck) and Ia (axilla) are assigned to local field radiotherapy. Patients with neck disease receive 30 Gy midline in sixteen fractions over 3 weeks followed by an additional 5 Gy to the site of palpable disease. Patients with axillary disease receive 35 Gy midline in sixteen fractions over 3 weeks.

2. Group B: Patients with pathological stage Ia (supraclavicular), IIa (all sites except neck) are assigned to mantle radiotherapy. Patients receive a dose of 35 Gy mid line in twenty fractions over 4 weeks followed by an additional 6 Gy to the anterior mediastinum.

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s))
Not provided at time of registration

Completion date
31/12/2001

Eligibility

Key inclusion criteria
1. Pathological stage Ia and IIa (upper) Hodgkin's disease
2. Aged 15 to 65 years

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex

Key exclusion criteria
Patients with mediastinal disease will not in general be eligible for local radiotherapy alone

Date of first enrolment
01/01/1998

Date of final enrolment
31/12/2001

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Cancer Research UK (CRUK) (UK)

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2005		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes